Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.
Publication
, Journal Article
Rivera-Chaparro, ND; Ericson, J; Wu, H; Smith, PB; Clark, RH; Benjamin, DK; Cohen-Wolkowiez, M; Greenberg, RG
Published in: Pediatr Infect Dis J
February 2019
Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Pediatr Infect Dis J
DOI
EISSN
1532-0987
Publication Date
February 2019
Volume
38
Issue
2
Start / End Page
e26 / e28
Location
United States
Related Subject Headings
- Pediatrics
- Micafungin
- Male
- Infant
- Humans
- Hospitalization
- Female
- Electronic Health Records
- Candidiasis
- Antifungal Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Rivera-Chaparro, N. D., Ericson, J., Wu, H., Smith, P. B., Clark, R. H., Benjamin, D. K., … Greenberg, R. G. (2019). Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. Pediatr Infect Dis J, 38(2), e26–e28. https://doi.org/10.1097/INF.0000000000002045
Rivera-Chaparro, Nazario D., Jessica Ericson, Huali Wu, P Brian Smith, Reese H. Clark, Daniel K. Benjamin, Michael Cohen-Wolkowiez, and Rachel G. Greenberg. “Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.” Pediatr Infect Dis J 38, no. 2 (February 2019): e26–28. https://doi.org/10.1097/INF.0000000000002045.
Rivera-Chaparro ND, Ericson J, Wu H, Smith PB, Clark RH, Benjamin DK, et al. Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. Pediatr Infect Dis J. 2019 Feb;38(2):e26–8.
Rivera-Chaparro, Nazario D., et al. “Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.” Pediatr Infect Dis J, vol. 38, no. 2, Feb. 2019, pp. e26–28. Pubmed, doi:10.1097/INF.0000000000002045.
Rivera-Chaparro ND, Ericson J, Wu H, Smith PB, Clark RH, Benjamin DK, Cohen-Wolkowiez M, Greenberg RG. Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records. Pediatr Infect Dis J. 2019 Feb;38(2):e26–e28.
Published In
Pediatr Infect Dis J
DOI
EISSN
1532-0987
Publication Date
February 2019
Volume
38
Issue
2
Start / End Page
e26 / e28
Location
United States
Related Subject Headings
- Pediatrics
- Micafungin
- Male
- Infant
- Humans
- Hospitalization
- Female
- Electronic Health Records
- Candidiasis
- Antifungal Agents